Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.01 USD | -1.17% | -4.92% | +47.42% |
Sales 2024 * | 551M 752M | Sales 2025 * | 590M 804M | Capitalization | 2.37B 3.23B |
---|---|---|---|---|---|
Net income 2024 * | -174M -237M | Net income 2025 * | -183M -249M | EV / Sales 2024 * | 3.91 x |
Net cash position 2024 * | 212M 289M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.01 x |
P/E ratio 2024 * |
-13.6
x | P/E ratio 2025 * |
-12.8
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on NovoCure Limited
1 day | -1.17% | ||
1 week | -4.92% | ||
1 month | +72.76% | ||
3 months | +35.45% | ||
6 months | +76.08% | ||
Current year | +47.42% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 63 | 11-08-04 |
David Hung
BRD | Director/Board Member | 67 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 17 M€ | +6.09% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 22.01 | -1.17% | 1,483,720 |
24-05-30 | 22.27 | +1.18% | 1,206,916 |
24-05-29 | 22.01 | -1.39% | 1,590,411 |
24-05-28 | 22.32 | -3.59% | 1,537,470 |
24-05-24 | 23.15 | +3.77% | 816,024 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.42% | 2.37B | |
+75.69% | 12.57B | |
-24.68% | 7.34B | |
+12.58% | 5.39B | |
-16.63% | 4.84B | |
+26.90% | 4.53B | |
-21.14% | 3.91B | |
-22.99% | 2.91B | |
-0.37% | 2B | |
+6.21% | 1.91B |
- Stock Market
- Equities
- NVCR Stock